Drug Trial Radar · NCT01818492
Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis
Last checked: Nov 20, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Jul 2013
Primary completion
Jan 2019
Study completion Jan 2019
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- Collaborators
- Seventh Framework Programme
- First posted
- Mar 26, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and efficacy of a new drug aimed at controlling disease activity in patients diagnosed with primary haemophagocytic lymphohistiocytosis. The new drug can be administered as the first-line therapy, to patients not previously treated with the current standard of care, or can be given to patients who have either failed or were unable to tolerate the current standard of care. Administration will be on top of a glucocorticosteroid, which is usually part of the current recommended treatment.
Conditions
- Primary Haemophagocytic Lymphohistiocytosis
Interventions
NI-0501Biological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) Second LineTime frame: End of Treatment (3 days after the last infusion of emapalumab in study NI-0501-04, occurring between 4 and 8 weeks)
- Overall Response Rate (ORR) All TreatedTime frame: End of Treatment (3 days after the last infusion of emapalumab in study NI-0501-04, occurring between 4 and 8 weeks)
- Overall Response Rate (ORR) Follow-on Analysis Set:Time frame: End of Treatment (3 days after the last infusion of emapalumab in study NI-0501-04, occurring between 4 and 8 weeks)
- Overall Response Rate (ORR) at End of Treatment in Study NI-0501-04 (EOT 04) Follow-on Analysis Set: All TreatedTime frame: End of Treatment (3 days after the last infusion of emapalumab in study NI-0501-04, occurring between 4 and 8 weeks)
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology
Wilmington, Delaware
Children's Healthcare of Atlanta
Atlanta, Georgia
Dana-Farber Cancer Institute (DFCI)
Boston, Massachusetts
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Cincinnati Children's Hospital - Division of Immunobiology - Department of Pediatrics
Cincinnati, Ohio
Texas Children's Cancer Center
Houston, Texas
Primary Children's Hospital
Salt Lake City, Utah
University Children's Hospital
Münster, Germany
Azienda Ospedaliero Universitaria Meyer
Florence, Italy
Istituto Giannina Gaslini
Genoa, Italy
Azienda Ospedaliera San Gerardo
Monza, Italy
Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica
Padua, Italy
Ospedale Pediatrico Bambino Gesu'
Roma, Italy
Ospedale Donna Bambino - U.O.C. Oncoematologia Pediatrica
Verona, Italy
Hospital Sant Joan de Déu
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Universitario Niño Jesús
Madrid, Spain
Karolinska University Hospital
Stockholm, Sweden
Great Ormond Street Hospital - Department of Haematology
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.